Equities analysts predict that Amyris Inc (NASDAQ:AMRS) will post ($0.37) earnings per share for the current quarter, Zacks reports. Two analysts have made estimates for Amyris’ earnings. Amyris posted earnings of ($0.17) per share in the same quarter last year, which indicates a negative year over year growth rate of 117.6%. The business is scheduled to report its next quarterly earnings results on Thursday, March 21st.
According to Zacks, analysts expect that Amyris will report full-year earnings of ($1.19) per share for the current fiscal year. For the next year, analysts forecast that the firm will report earnings of ($0.19) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Amyris.
Amyris (NASDAQ:AMRS) last released its earnings results on Tuesday, November 13th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.96). The company had revenue of $14.90 million for the quarter, compared to the consensus estimate of $46.72 million. The company’s quarterly revenue was down 38.4% compared to the same quarter last year. During the same period last year, the company earned ($0.81) earnings per share.
In other news, CFO Kathleen Valiasek bought 23,000 shares of the stock in a transaction dated Tuesday, November 27th. The stock was purchased at an average cost of $4.37 per share, for a total transaction of $100,510.00. Following the transaction, the chief financial officer now owns 251,630 shares of the company’s stock, valued at $1,099,623.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Eduardo Alvarez bought 11,834 shares of the stock in a transaction dated Thursday, December 13th. The shares were purchased at an average price of $4.23 per share, with a total value of $50,057.82. Following the completion of the transaction, the chief operating officer now directly owns 333,876 shares in the company, valued at approximately $1,412,295.48. The disclosure for this purchase can be found here. Corporate insiders own 21.80% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vivo Capital LLC boosted its position in shares of Amyris by 97.2% during the 3rd quarter. Vivo Capital LLC now owns 5,575,118 shares of the biotechnology company’s stock valued at $44,266,000 after acquiring an additional 2,748,407 shares during the last quarter. BlackRock Inc. raised its holdings in Amyris by 32.8% during the 3rd quarter. BlackRock Inc. now owns 2,277,432 shares of the biotechnology company’s stock valued at $18,082,000 after buying an additional 562,877 shares during the period. Gilder Gagnon Howe & Co. LLC purchased a new stake in Amyris during the 3rd quarter valued at $7,828,000. AWM Investment Company Inc. purchased a new stake in Amyris during the 3rd quarter valued at $5,876,000. Finally, Allianz Asset Management GmbH raised its holdings in Amyris by 56.0% during the 3rd quarter. Allianz Asset Management GmbH now owns 643,630 shares of the biotechnology company’s stock valued at $5,110,000 after buying an additional 231,145 shares during the period. Hedge funds and other institutional investors own 30.31% of the company’s stock.
Amyris stock traded up $0.27 during midday trading on Thursday, hitting $3.39. The stock had a trading volume of 1,317,250 shares, compared to its average volume of 838,869. The firm has a market capitalization of $238.97 million, a price-to-earnings ratio of -1.11 and a beta of 0.38. Amyris has a 52-week low of $2.64 and a 52-week high of $9.28.
Amyris, Inc, an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products.
Recommended Story: What is the Book Value of a Share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amyris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris and related companies with MarketBeat.com's FREE daily email newsletter.